INTRODUCTION

A heart is a highly complex structure composed of multiple types of cellular and acellular tissues. 1,2 Of cardiac components, cardiomyocyte is a major contributor to cardiac composition and output. 1 Non-myocytes such as fibroblasts, leucocytes and endothelial cells serve as a spatial buffer and more importantly modulate cardiomyocyte functions in response to physiological and pathological stimuli. Thus, cardiomyocytes and non-myocytes closely communicate to maintain cardiac homeostasis, and the imbalance in this communication causes cardiac diseases. 3 Metabolites such as nitric oxide and reactive oxygen species and signalling molecules including extracellular matrix proteins, cytokines and growth factors are known to be classic mediators of intercellular communication. 3,4 Recently, extracellular vesicles (EVs) emerged as a mechanism underlying this intercellular communication. Although EVs had incipiently been considered as a means of cellular waste disposal, accumulating data recently indicated that genetic cargos such as mRNAs, microRNAs (miRs), proteins, lipids, and antigens were transported by EVs. This transit of genetic materials by EVs has been identified to play critical roles in cell-cell communication, notably for cancer development, 5 and cardiovascular disease. 6-9 Notably, several miRs transported by EVs have been associated with a variety of cardiovascular diseases, including heart failure (HF). 6-9 However, it remains unclear what miRs are enriched in EVs and play an important role in the pathological condition. Therefore, we established the miR expression profiles in EVs from murine normal and failing hearts and consecutively identified substantially altered miRs. In addition, we have performed bioinformatics approach to predict potential cardiac outcomes through the identification of miR targets. Conclusively, we observed approximately 63% of predicted targets were validated with previous reports. Notably, the predicted targets by this approach were often involved in both beneficial and malicious signalling pathways, which may reflect heterogeneous cellular origins of EVs in tissues. Lastly, there has been an active debate on U6 whether it is a proper control. Through further analysis of EV miR profiles, miR-676 was identified as a superior reference control due to its consistent and abundant expressions. In summary, our results contribute to identifying specific EV miRs for the potential therapeutic targets in heart failure and suggest that miR-676 as a new reference control for the EV miR studies.

KEYWORDS
bioinformatics, extracellular vesicle, heart failure, microRNA, microRNA array, microRNA control, miR-676, U6
microRNAs (miRs) and proteins are transported by EVs. Therefore, EVs are being re-evaluated as a critical modifier of cellular functions. During last decade, tremendous efforts have been placed to understand the mechanism and the function of EVs in diverse fields of studies including cardiovascular researches. For example, EVs derived from stem cells or cardiac progenitor cells were generally beneficial, whereas EVs from fibroblasts or endothelial cells exhibited deleterious effects on cardiac functions. In these previous studies, the origin of EVs was confined to in vitro cultured cells or blood plasma, but the role of EVs in cardiac tissues has been poorly investigated. Therefore, it is important to characterize in tissue EVs under pathological conditions. Recently, Loyer X. et al characterized the functions of EVs isolated from mouse hearts subjected to myocardial infarction. In this study, we further analysed the expression profiles and functions of miRNAs in EVs isolated from pressure overload-induced failing hearts compared to normal hearts.

Apart from the characterization study, we also sought to identify an alternative internal reference for miR studies. In general, U6 is the most commonly used control for the normalization of miR expression. However, it is yet controversial whether U6 is a suitable control because variable expression patterns of U6 were observed in a number of studies. Analysing the abundance and stability of miR expression, U6 was confirmed as an appropriate control being consistently expressed throughout our samples. In addition, we identified miR-676 as an alternative candidate as a control and observed that it exhibited a significant correlation with U6. Taken together, although a further validation is necessary in other tissues or organs, miR-676 may serve as an alternative control for the EV miR studies in the heart.

In summary, this study analysed miR profiles in the cardiac EVs isolated from murine normal and failing hearts. Our results demonstrated that the cardiac EVs contain diverse miRs with contradictory functions. The results may reflect various cellular origins of EVs and dynamic alternations of miR expressions in these EVs during heart failure. Nevertheless, our study may contribute to understand intercellular communication between cardiac cells under the pathological condition and suggests EV miRs as potential biomarkers and therapeutic targets for the intervention of heart failure.

2 MATERIALS AND METHODS

2.1 Animal care and TAC

All procedures were approved by and performed in accordance with the Institutional Animal Care and Use Committee of the Mount Sinai School of Medicine. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Studies were conducted in male C57BL/6 mice aged 8 ~ 10 weeks (weight, 25 ~ 30 g) obtained from Jackson Laboratories. Transverse aortic constriction (TAC) was conducted as previously described with minor modifications. Briefly, mice were anesthetized with a solution mixture of 95 mg/kg ketamine and 5 mg/kg xylazine administered via intraperitoneal injection. The transverse aortic arch was ligated between the innominate and left common carotid arteries with an overlying 27-gauge needle. The needle was then immediately removed, leaving a discrete region of constriction. Two month after TAC operation, the mice showed less than 40% of fractional shortening in average which is typically considered as failing heart and included in this study (Figure S3). Sham-operated mice underwent the same surgical procedures, except that the ligature was not tied.

2.2 EV isolation and purification

To isolate in tissue cardiac EVs from the heart tissue, Langendorff-based isolation was applied as utilizing previous protocol to isolate in tissue EV from liver. Hearts were extracted from sham or TAC-operated animals, and the aorta was retrogradely perfused at 37°C for 3 minutes with Tyrode buffer (137 mmol/L NaCl, 5.4 mmol/L KCl, 1 mmol/L MgCl₂, 10 mmol/L glucose, 10 mmol/L HEPES [pH 7.4], 10 mmol/L 2,3-butanedione monoxime, and 5 mmol/L taurine) gassed with 100% O₂. The enzymatic digestion was initiated by the addition of collagenase type B (300 U/mL; Worthington) and hyaluronidase (0.1 mg/mL; Worthington) and gassed with 100% O₂. The mixtures of cell, extracellular matrix and EVs were then separated by several centrifugations according to a previously described protocol. EVs were pelleted by ultracentrifugation at 100 000 × g at 4°C for 90 minutes and resuspended in 200 μL of PBS solution.

2.3 Transmission Electron microscopy for EVs with negative staining

EVs from fresh ventricles were collected as described above and pre-fixed with 2% paraformaldehyde (PFA) for 30 minutes. Deposit 5 μL resuspended pellets on Formvar-carbon-coated EM grid. Add 10 μL of 2% uranyl acetate on the grid and incubate for another 10 minutes. After thorough washes, store grid in the grid box at room temperature and dark until imaging. Samples were viewed under a transmission electron microscope (HITACHI H-7650, Japan) operated at 80 kV. Images were taken at 10K, 20K and 30K-folds magnification.

2.4 Western blot of EV markers and Coomassie blue stain

50 μL of EV samples from Sham and TAC EV was directly mixed with 5x SDS sample buffer, boiled at 95°C for 3 minutes and then separated on a SDS-PAGE gel. The total loaded protein amount was calculated by the intensity of Coomassie blue stain. The membrane
was blocked in 5% skim milk solution and incubated overnight with an antibody directed against hnRNA A2B1 (Ab6102, Abcam, 1:5000), CD63 (Ab1318, Abcam, 1:1000), Flotillin 1 (Ab133497, Abcam, 1:10 000), TSG101 (Ab83, Abcam, 1:1000), H3 (Ab1791, Abcam, 1:1000) and SERCA2a (custom antibody from 21st Century Biochemicals, 1:3000). The membrane was then incubated with a horseradish peroxidase-conjugated secondary antibody (Sigma) and developed with Western Lighting chemiluminescence reagent (PerkinElmer).

2.5 | Nanoparticle tracking analysis

Samples were loaded into the assembled sample chamber of a NanoSight LM10. 60-second video images were acquired by a Hamamatsu C11440 ORCA-Flash 2.8 digital camera and analysed by NanoSight NTA 2.3 software.

2.6 | Extracellular vesicle microRNA isolation and microRNA array profiling

100 μL of EV samples from Sham and TAC EV was used to extract RNA for microRNA array profiling and validation using qRT-PCR. Total EV RNA was isolated with mirVana miRNA Isolation Kit (Ambion). The RNA samples were sent, and the microarray procedure was carried out at Exiqon Vedbaek, Denmark, as followed the previous description. Briefly, the samples were labelled using the miRCURY LNA™ microRNA Hi-Power Labeling Kit, Hy3™/Hy5™ and hybridized on the miRCURY LNA™ microRNA Array (7th Gen).

2.7 | qRT-PCR

Total RNA was isolated with mirVana miRNA Isolation Kit (Ambion). Reverse transcription was performed using qScript microRNA cDNA Synthesis Kit (Quanta). PCR was performed using an ABI PRISM Sequence Detector System 7500 (Applied Biosystems) with SYBR Green (Quanta) as the fluorescent dye and ROX (Quanta) as the passive reference dye. The relative amount of each gene to U6 snRNA was used to quantify cellular RNA. The primers used for qRT-PCR were as follows:

- miR-92b (forward): 5′-TAT TGC ACT CGT CCT GGC CTC C-3′
- miR-139 (forward): 5′-TCT ACA GTG CAC GTG TCT CCA G-3′
- miR-328 (forward): 5′-CTG GCC CTC TCT GCC CTT CCG T-3′
- miR-331 (forward): 5′-CTA GTG ATG GCA CCG ATC C-3′
- miR-345 (forward): 5′-GCT GAC CCC TAG TCG AGT GCT T-3′
- miR-378a (forward): 5′-ACT GCA GGT GTC GCA AGA AGG-3′
- miR-490 (forward): 5′-CCA TGG ATC TCC AGG TGC GT-3′
- miR-655 (forward): 5′-ACC AGG AGG CTT GAG TCC CT-3′
- miR-767 (forward): 5′-TGC ACC ATG GTC TGA GCA-3′
- miR-874 (forward): 5′-CTG CCC TGG CCC GAG GGA CGC A-3′
- miR-99b (forward): 5′-ACC CGG TAG ACC GCA CCT TGC G-3′

2.8 | Bioinformatics analysis

The global UP and DOWN cardiac microRNA target genes were generated using miTarBase (Http://mitarbase.mbc.nctu.edu.tw). Bioinformatics analyses (Gene Ontology) were performed using the UniProt database and Human Protein Reference Database. Protein-protein interactions analyses by STRING 11.0 database with medium confidence STRING annotated interactions (STRING score > 0.4) for the bait proteins. Cytoscape software (Ver 3.6.1; http://www.cytoscape.org/) was used to visualize the network.

2.9 | Statistical analysis

Where appropriate, the data are expressed as means ± s.e.m. Comparisons of the group means were made by using Student’s t test or one-way ANOVA with a Bonferroni post-test analysis. Correlation test was performed with the Pearson’s correlation coefficient measure. A P-value of <.05 was considered to be statistically significant.

3 | RESULTS

3.1 | Cardiac EVs from normal and failing hearts have distinctive physical and molecular signatures

Pressure overload-induced heart failure was generated in murine hearts by applying transverse aortic constriction (TAC). The cardiac EVs were isolated from normal (Sham EVs) and failing (TAC EVs) hearts using the Langendorff-based isolation followed by purification through multiple rounds of ultracentrifugations (Figure 1A). The isolated EVs were negatively stained and visualized by electron microscopy with 30 000-fold magnification. Morphological analysis revealed that EVs showed a typical cup-shaped structure with a diameter of 70 ~ 160 nm and that TAC EVs tended to be larger than Sham EVs (Figure 1B). Nanoparticle tracking analysis (NTA)
was performed to precisely measure the concentration and sizes of EVs. Failing hearts secrete ~5 × 10⁹ EVs per heart, whereas normal hearts release ~2 × 10⁹ EVs per heart (Figure 1C). Average size of TAC EVs was significantly larger than that of Sham EVs, which is consistent with the electron microscopic data (Figure 1D upper panel). Size distribution profiles of EVs indicated that the majority of EVs were 100 nm in size in both Sham and TAC groups. Two additional groups of Sham EVs were 150 nm and 200 nm in size. On the other hand, one group of 130 nm in size was additionally observed in TAC EVs (Figure 1D, black arrow; Sham EVs, red arrow; TAC EVs). Furthermore, Sham and TAC EVs exhibited a significant difference in their protein contents. Same volumes of EV samples (50 μL, a quarter of the total EVs from a heart) were loaded in a SDS-PAGE gel and quantified by Coomassie blue staining. In line with NTA results, 50% more proteins were detected in TAC EVs (Figure 1E and F). As shown in Figure 1F, several EV markers were analysed by Western bolt analysis. The Flotillin level was not altered between Sham and TAC EVs, but hnRNP A2B1 expression was significantly increased in TAC EVs. On the other hand, TSG101 and CD63 expressions were substantially reduced in TAC EVs (Figure 1F). Taken together, the cardiac EVs from normal and failing hearts showed distinctive features in their physical and molecular properties.

### 3.2 microRNA profiles of cardiac EVs and validation

To further characterize cardiac EVs, microRNA (miR) expression profiles were explored. Cardiac EVs were isolated from three normal and three failing hearts. All EV preparations were immediately subjected to quality control and miRNA array analyses that were conducted using the 7th generation of miRCURY™ LNA array system.
Of the 1,195 miRs displayed on the array, 731 miRs were eliminated due to a lack of significant signal intensity. The remaining 464 miRs were then sorted out by criteria indicated in Figure 2A (Table S1). The heat map diagram demonstrated a clear separation of miR expressions in Sham and TAC EVs (Figure 2B). Compared to Sham EVs, 107 miRs were up-regulated (23%) and 47 miRs were down-regulated (10%) in TAC EVs (Figure 2C). miRs with p-values higher than 0.05 were considered as ‘not altered’ (67%). The 154 miRs differentially expressed on the array were further validated for their abundancy using qRT-PCR. Consequently, we identified seven up-regulated (miR-378a, miR-665, miR-139, miR-345, miR-328, miR-767 and miR-92b) and three down-regulated (miR-99b, miR-124 and miR-411) miRs (Figure 3A and B).

3.3 Potential target prediction for the identified miRs

To investigate the roles of the identified miRs under pathological conditions, bioinformatics analyses were performed as shown in Figure 4A (Tables 1 and 2). First, putative targets listed in miRTarBase (http://mirtarbase.mbc.nctu.edu.tw) as validated by both reporter assay and Western blot analysis were selected. Second, the selected targets were further sorted out according to their tissue distribution as reported in the proteomics database (www.proteomicsdb.org). Through these two subsequent analyses, 29 putative targets associated with the seven up-regulated miRs and 49 putative targets associated with the three down-regulated miRs were identified. Lastly, these putative targets were categorized based on their subcellular localization, biological process and protein-protein interactions (Tables 3 and 4). The analysis of subcellular localization revealed that miRs of TAC EVs appeared to target proteins predominantly located in the plasma membrane, nucleus and cytoskeleton (Figure 4B). Functional analysis suggested that target proteins for the up-regulated miRs were involved in cell cycle (19%), signal transduction (15%) and apoptosis (15%). On the other hand, intracellular targets for the down-regulated miRs were predicted to contribute to transcription/translation (22%), apoptosis (18%) and cell cycle (14%) (Figure 4 and D). The protein-protein interaction map generated by the STRING database (https://string-db.org/) is shown in Figure 5. The most frequently matched targets controlled by the up-regulated miRs in TAC EVs were NOTCH, CD44 and PTEN. Meanwhile, targets modulated by the down-regulated miRs were CDH2, GRB2 and ITGB1. Taken together, these results suggest that miRs in TAC EVs are indeed closely related to the essential biological processes.
Identification of an alternative control for miR expression

There is no clear consensus on suitable controls for relative miR quantification in circulating miRs, although U6 has been considered as an endogenous normalization control. In this study, we tested whether U6 is an adequate control for the miR expression. U6 expression was shown to be abundant, stable and not significantly different across all 12 EV samples (Figure 6A). Therefore, U6 expression was used to normalize the qRT-PCR data presented in Figure 3. To further support and strengthen our results, we searched out potential candidates for more reliable controls that showed minimal differences in expressions between groups yet with strong signal intensity. Initial screening led us to identify five miRs, miR-676, miR-300, miR-204, miR-453 and miR-3085. Those were thoroughly tested and validated by qRT-PCR with multiple primer sets, and finally, miR-676 was selected as a new potential candidate for a EV miR expression control. As shown in Figure 6A, miR-676 indeed exhibited the most invariable expressions throughout all samples, which is comparable to U6. (Figure B and C). In fact, in regard to Ct values obtained by the Mann-Whitney test between Sham and TAC EVs, miR-676 expression ($P = .52$) was more consistent than U6 expression ($P = .11$). These data suggest that miR-676 can be used as an internal control for EV miRs with high fidelity.

### DISCUSSION

As EVs are highlighted as an important mediator of cell-to-cell communications during heart failure, it becomes essential to analyse the contents of cardiac EVs. In the present study, we isolated and characterized cardiac EVs from normal and failing mouse hearts. In the physical and molecular analyses, TAC EVs showed distinctive features in terms of density, size, protein expression patterns and miR contents as compared to those from Sham EVs (Figure 1). EVs are bound to cell surface proteins, extracellular matrix (ECM) molecules and components of the blood plasma through its surface molecules, and located in the niche of ECM or plasma. Several studies have characterized circulating EVs or miRs during cardiac diseases, but available

| Name         | $P$-Value | Targets                                                                 |
|--------------|-----------|-------------------------------------------------------------------------|
| miR-767-5p   | 1.7E-05   | ABCG2, CD44, H2AFX, KCNH2, MMP16, PLCE1, SFRP1                           |
| miR-32b-3p   | 1.9E-05   | CDKN1C, CEBPB, DAB2IP, DKK3, ITGA6, NLK, NOX4, PTEN, RECK, SLC15A1, SMAD3 |
| miR-92b-3p   | 2.0E-05   | ADGRL4, BCL2, CXCR4, FOXO1, IGF1R, IRS1, JUN, MCL1, MET, MMP11, NOTCH1, NR5A2, OIP5, PAFAH1B1, RAP1B, ROCK2, TPD52, WNT1 |
| miR-139-5p   | 2.2E-05   | ADGRL4, BCL2, CXCR4, FOXO1, IGF1R, IRS1, JUN, MCL1, MET, MMP11, NOTCH1, NR5A2, OIP5, PAFAH1B1, RAP1B, ROCK2, TPD52, WNT1 |
| miR-665-3p   | 2.2E-05   | CDK6, GALNT7, IGF1R, MAPK1, NPNT, NRF1, PGR, RUNX1, TGFβ2, VEGFA, VIM, WNT10A |
| miR-345-5p   | 1.3E-04   | ABCC1, CDKN1A                                                             |

| Name         | $P$-Value | Targets                                                                 |
|--------------|-----------|-------------------------------------------------------------------------|
| miR-99b-5p   | 6.4E-06   | ARID3A, IGF1R, MFGE8, MTOR, RAVER2                                       |
| miR-124-3p   | 8.7E-04   | ABHD5, ADIPOR2, AHR, AKT2, AMOTL1, AR, B4GALT1, CAMTA1, CAV1, CBL, CCL2, CCNA2, CCND2, CD151, CDH2, CDK2, CDK4, CDK6, CEBPA, CLOCK, DLX5, E2F6, EFNB1, EGR1, EZH2, FLT1, FOXA2, HMGAl, HRNPNP2B1, HOTAIR, IL6R, IQGAP1, ITGB1, JAG1, LAMC1, MAPK14, MTDH, MTFN, MYO10, Nfatc1, NFkbiz, NR3C1, NR3C2, PEA15, PIK3CA, PNPLA2, PPP1R13L, PRRX1, PTBP1, PTBP2, RAB3B, RAP2A, RHOG, ROCK1, ROCK2, RRAS, SART3, SIRT1, SLC16A1, SMOX, SMYD3, SOS1, SPHK1, SSSCA1, STAT3, SYCP1, TRIB3, UHRF1, VAMP3, VIM |
| miR-411-5p   | 3.3E-05   | GRB2                                                                     |

**TABLE 1** Up-regulated miRs in TAC EV and their targets

**TABLE 2** Down-regulated miRs in TAC EV and their targets
information was highly limited since most of the studies were conducted using blood plasma.\textsuperscript{26,27} Recently, Loyer X. et al investigated cardiac EVs in the model of myocardial infarction.\textsuperscript{13} In their report, they minced ventricles to obtain cardiac EVs, which might damage cardiac cells and increase potential contaminants from other intracellular components. In our study, on a contrary, Langendorff-based EV isolation was employed to minimize damaging cells (Figure 1A). In addition, we have also compared our data with a previous study about the circulating miRs in a canine heart failure model.\textsuperscript{27} However, only thirteen miRs were confirmed to be identical out of fifty seven miRs reported in this paper (Table S1). This weak correlation suggests distinctive miR profiles of EVs in the ECM and plasma, which is probably due to different cellular origins of EVs. Plasma EVs could be released from the other organ or tissues, but EVs used for our study is strictly from cardiac tissues. In a similar context, we found the different size distribution and protein profiles between Sham and TAC EVs (Figure 1D-F). In fact, our NTA data showed that the size of EVs in HF is larger than that of Sham. Previously, Minghua et al showed that

| Table 3 | Putative targets of the up-regulated miRs and their localization, biological process and cardiac expression |
| --- | --- | --- | --- | --- |
| **Up-regulated microRNAs** | **Target Genes** | **Primary Localization** | **Primary Biological Process** | **Cardiac Expression** | **Expression in Failing Heart** | **Reference** |
| miR-92b-3p | CDKN1C | Nucleus | Cell cycle | 4.36 | Down | [53] |
|  | CEBPB | Nucleus | Transcription and translation | 4.63 | Down | [55] |
|  | DAB2IP | Plasma membrane | Angiogenesis | 3.74 | No study | |
|  | DKK3 | Extracellular | Signal transduction | 4.03 | Down | [54] |
|  | ITGA6 | Plasma membrane | Cell adhesion | 4.35 | No study | |
|  | PTEN | Plasma membrane | Apoptosis | 4.43 | Down | [52] |
|  | RECK | Plasma membrane | Angiogenesis | 3.34 | No study | |
|  | SMAD3 | Nucleus | Transcription and translation | 4.17 | Up | [59] |
| miR-139-5p | BCL2 | Cytosol | Apoptosis | 3.94 | Down | [56] |
|  | IGF1R | Plasma membrane | Signal transduction | 3.98 | Up | [41] |
|  | MCL1 | Mitochondrion | Apoptosis | 3.42 | Down | [57] |
|  | NOTCH1 | Nucleus | Angiogenesis | 2.97 | Up | [60] |
|  | PAAH1B1 | Cytoskeleton | Cell cycle | 5.44 | No study | |
|  | RAP1B | Plasma membrane | Signal transduction | 5.47 | No study | |
|  | ROCK2 | Plasma membrane | Apoptosis | 4.38 | Up | [42] |
|  | TPD52 | Endoplasmic reticulum | Differentiation | 4.97 | No study | |
| miR-328-3p | CD44 | Plasma membrane | Cell adhesion | 4.3 | Up | [61] |
|  | H2AFX | Nucleus | Cell cycle | 4.6 | No study | |
|  | MMP16 | Plasma membrane | Proteolysis | 3.08 | No study | |
|  | SFRP1 | Plasma membrane | Differentiation | 4.88 | No change | |
| miR-345-5p | ABCC1 | Plasma membrane | Transport | 3.66 | No study | |
| miR-378a-3p | CDK6 | Cytoskeleton | Cell cycle | 5.01 | No study | |
|  | GALNT7 | Golgi apparatus | Metabolic process | 2.89 | No study | |
|  | IGF1R | Plasma membrane | Signal transduction | 3.98 | Up | [41] |
|  | MAPK1 | Cytoskeleton | Apoptosis | 5.14 | Up | [35] |
|  | NPNT | Extracellular | Cell adhesion | 4.05 | No study | |
|  | Nrfl | Nucleus | Transcription and translation | 4.29 | Up | [62] |
|  | VIM | Cytoskeleton | Signal transduction | 7.38 | Up | [47] |
| Target-regulated microRNAs | Target Genes | Primary Localization | Primary Biological Process | Cardiac Expression | Expression in Failing Heart | Reference |
|----------------------------|--------------|----------------------|---------------------------|-------------------|---------------------------|-----------|
| miR-99b-5p                 | ARID3A       | Nucleus              | Transcription and translation | 3.08              | No Study                  | [41]      |
|                            | IGFR1        | Plasma membrane      | Immune response           | 3.98              | Up                        | [63]      |
|                            | MGE8         | Cytoskeleton         | Angiogenesis              | 4.51              | Down                      | [63]      |
|                            | MTOR         | Nucleus              | Cell cycle                | 3.48              | up                        | [46]      |
| miR-124-3p                 | ABHD5        | Cytosol              | Differentiation           | 2.66              | Down                      | [44]      |
|                            | AKT2         | Nucleus              | Apoptosis                 | 3.87              | No Study                  | [63]      |
|                            | AMOTL1       | Cytosol              | Angiogenesis              | 2.88              | No Study                  | [64]      |
|                            | B4GALT1      | Plasma membrane      | Development               | 3.79              | No Study                  | [45]      |
|                            | CAV1         | Plasma membrane      | Immune response           | 6.78              | Down                      | [65]      |
|                            | CBL          | Golgi apparatus      | Signal transduction       | 3.59              | Up                        | [50]      |
|                            | CD151        | Plasma membrane      | Cell adhesion             | 4.82              | Controversial             |           |
|                            | CDH2         | Plasma membrane      | Cell adhesion             | 5.96              | Up                        | [43]      |
|                            | CDK2         | Nucleus              | Cell cycle                | 4.34              | UP                        | [48]      |
|                            | CDK4         | Nucleus              | Cell cycle                | 4.11              | No change                 | [66]      |
|                            | CDK6         | Nucleus              | Cell cycle                | 5.01              | No Study                  |           |
|                            | EFNB1        | Plasma membrane      | Differentiation           | 4.42              | No study                  |           |
|                            | FLOT1        | Plasma membrane      | Immune response           | 5.34              | No Study                  |           |
|                            | HMGAT1       | Nucleus              | Transcription and translation | 5.49            | Down                      | [67]      |
|                            | HNRNPA2B1    | Extracellular        | Transcription and translation | 6.57            | No Study                  |           |
|                            | IQGAP1       | Plasma membrane      | Immune response           | 4.56              | No Study                  |           |
|                            | ITGB1        | Plasma membrane      | Cell adhesion             | 5.68              | No Study                  |           |
|                            | LAMC1        | Extracellular        | Cell adhesion             | 6.25              | No Study                  |           |
|                            | MAPK14       | Nucleus              | Apoptosis                 | 4.97              | Up                        | [44]      |
|                            | MTDH         | Nucleus              | Apoptosis                 | 4.25              | No Study                  |           |
|                            | MTPN         | Cytoskeleton         | Transcription and translation | 5.6              | No Study                  |           |
|                            | NR3C1        | Nucleus              | Apoptosis                 | 4.26              | No Study                  |           |
|                            | PEA15        | Cytoskeleton         | Apoptosis                 | 5.43              | No Study                  |           |
|                            | PIK3CA       | Cytosol              | Angiogenesis              | 2.89              | Up                        | [51]      |
|                            | PPP1R13L     | Extracellular        | Apoptosis                 | 4.06              | No Study                  |           |
|                            | PRRX1        | Nucleus              | Transcription and translation | 4.03            | No Study                  |           |
|                            | PTBP1        | Nucleus              | Transcription and translation | 5.69            | No Study                  |           |
|                            | PTBP2        | Nucleus              | Transcription and translation | 4.98            | No Study                  |           |
|                            | RAP2A        | Plasma membrane      | Signal transduction       | 4.3               | No Study                  |           |
|                            | RHOG         | Plasma membrane      | Transcription and translation | 5.07            | No Study                  |           |
|                            | ROCK1        | Cytoskeleton         | Apoptosis                 | 4.25              | UP                        | [42]      |
|                            | ROCK2        | Plasma membrane      | Apoptosis                 | 4.38              | UP                        | [42]      |
|                            | RRAS         | Plasma membrane      | Differentiation           | 5.33              | No Study                  |           |
|                            | SART3        | Nucleus              | Transcription and translation | 4.07            | Up                        | [45]      |
|                            | SIRT1        | Nucleus              | Apoptosis                 | 3.37              | Up                        | [49]      |
|                            | SLC16A1      | Plasma membrane      | Transport                 | 5.16              | No Study                  |           |
|                            | SMYD3        | Nucleus              | Transcription and translation | 3.99            | No Study                  |           |

(Continues)
size of exosomes were changed in remote ischaemic preconditioning-mediated cardioprotection, which is correlated with our morphological observations. Taken together, these differences are also presumably related to the dynamic changes in the cellular composition of the heart under pathological conditions. In addition, we also observed the differences in the expression of exosomal markers. For example, CD63 and TSG101 were decreased in TAC EVs and these markers were previously reported to be involved in cardiac fibrosis and hypertrophy, respectively. On the other hand, hnRNP A2B1 expression was increased and this was known to control the sorting of miRs into exosomes through specific binding motif. Although we particularly focused on miR profiles in EVs, this result also suggests a possibility that proteins in EVs could actively regulate cardiac intercellular communication.

From EV miR profiles, we have identified seven up-regulated and three down-regulated miRs in failing hearts compared to controls. Briefly, miR-757, miR-328, miR-92b, miR-139, miR-665, miR-378a and miR-345 were up-regulated, whereas, miR-99b, miR-124 and miR-411 were down-regulated during heart failure (Tables 1 and 2). Among the seven up-regulated miRs, three miRs (miR-92b, miR-139 and miR-378a) are known to be anti-hypertrophic and another three miRs (miR-139, miR-378a and miR-345) are anti-fibrotic (Table 5). These data indicate that up-regulated miRs are likely involved in the cardioprotective function. Interestingly, one
of down-regulated miRs, miR-124, is also known to induce cardiac hypertrophy,\textsuperscript{38} attenuate cardiac function and stimulate angiogenesis.\textsuperscript{39} Therefore, EV miRs released from failing hearts may play important roles in cardioprotection (Table 5). On the other hand, a negative-inotropic miR, miR-328, was found to be increased and an anti-fibrotic miR, miR-411, was decreased. In addition, we evaluated EV miR-146a, a negative-inotropic miR, that we previously reported,\textsuperscript{10} as a positive control and it was also significantly increased (Figure S1). Therefore, even though anti-hypertrophic and anti-fibrotic EV miRs are mainly elevated in TAC EVs, the negative-inotropic and pro-fibrotic miRs are also enriched. These ambivalent features of TAC EVs may result from diverse cellular origins of EVs, and EV miRs are meticulously balanced in normal heart. This finding is in line with the previous reports that EVs from cardiac stem cells are normally salubrious and the EVs from fibroblasts and endothelial cells are deleterious.\textsuperscript{4,6–10,12}

Furthermore, bioinformatics was applied as an alternative approach to predict the impact of EV miRs on cardiac function. First, we predicted the possible cardiac outcomes with previously reported targets for miRs identified in this study. Next, we performed literature studies and compared with previous results. In brief, molecular targets experimentally validated by both a reporter assay and Western blot analysis were initially selected based on the miR database (miRTarBase) and 52 targets that are not expressed in the heart were discarded. The remaining 77 putative targets of EV miRs are summarized in Table 3 (targets for up-regulated miRs) and Table 4 (targets for down-regulated miRs). Intriguingly, approximately 72% of targets anticipated to be up-regulated were confirmed to be elevated indeed in diseased conditions by previous reports,\textsuperscript{40–51} and 50% of targets expected to be down-regulated were actually reduced.\textsuperscript{52–57} This result proves that EV miRs from failing hearts substantially affect gene expressions in the heart.

Lastly, there have been controversial reports for the usage of U6 although it is the most frequently used endogenous reference control.\textsuperscript{14–19} For example, U6 expression was not stable in tissues or plasma from patients with cancer.\textsuperscript{14,15,17} Therefore, we deliberated an extra assessment for the evaluation of EV miR expression. Initially, U6 was confirmed to be abundant and stable in our samples and used as a reference control in this study. To avoid potential critics for the usage of U6, we decided to identify alternative reference miR. Through the miRNA profile analysis, miR-676 was appeared as a promising candidate due to its superior abundance and stability. Upon this result, additional normalization was performed using miR-676 (Figure S2) and a significant correlation between U6 and miR-676 was confirmed. Although miR-676 is reported to be elevated in the liver in the response to a high-fat diet,\textsuperscript{58} there are no reports relating to cardiac function. Therefore, miR-676 may be a suitable reference in EV miR research although further validations are necessary in various cardiac diseases.

| Up-regulated microRNAs | Contractility | Hypertrophy | Fibrosis | Reference |
|------------------------|--------------|-------------|----------|-----------|
| miR-92b                | Unknown      | ↓           | -        | [33]      |
| miR-139                | Unknown      | ↓           | ↓        | [32,36]   |
| miR-378a               | Unknown      | ↓           | ↓        | [34,35]   |
| miR-345                | Unknown      | Unknown     | ↓        | [37]      |
| miR-328                | ↓            | ↑           | ↑        | [68,69]   |

| Down-regulated microRNAs | Hypertrophy | Fibrosis | Reference |
|--------------------------|-------------|----------|-----------|
| miR-124                  | ↑           | ↑        | [38,39]   |
| miR-411                  | Unknown     | Unknown  | ↓ [70]    |

TABLE 5  Previously described functions of differentially expressed miRs in TAC EV
In summary, we isolated and characterized cardiac EVs in the context of miR contents using normal and failing hearts. EVs from both hearts exhibited substantial contrasts in physical and functional features. We also found that EVs from failing hearts contains both beneficial and detrimental miRs presumably because current EV miR profiles that we reported here were generated from mixed cellular origins in failing hearts, which is a limitation of this study.

Taken together, our study shows dynamic intercellular communications via EV miRs during heart failure and it will be critical to identify the origin of beneficial EVs for a therapeutic application to treat heart failure.

ACKNOWLEDGEMENTS
This work is supported by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, through the FY17, DMDRP, Career Development Award programme under Award No. W81XWH-18-1-0322. C. K was supported by the American Heart Association (AHA) 18TPA34170460 and the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, through the FY18, CDMRP, Investigator-Initiated Research Award: No. W81XWH-19-1-0382.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS
JGO, PL and DJ designed the research, performed the experiments, analysed the data and wrote the paper. REG contributed in performing EM microscopy. SS and CK served as scientific advisor. DJ revised a manuscript and data.

DATA AVAILABILITY STATEMENT
All data generated or analysed during this study are included in this published article (and its supplementary information files). Furthermore, the raw data sets generated during the current study are also available from the corresponding author on reasonable request.

ORCID
Dongtak Jeong https://orcid.org/0000-0003-4153-3498

REFERENCES
1. Zhou P, Pu WT. Recounting cardiac cellular composition. Circ Res. 2017;118(3):368-370.
2. Rienks M, Papageorgiou AP, Frangogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114(5):872-888.
3. Tian Y, Morrisey EE. Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res. 2012;110(7):1023-1034.
4. Bang C, Antoniades C, Antonopoulos AS, et al. Intercellular communication lessons in heart failure. Eur J Heart Fail. 2015;17(11):1091-1103.
5. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
6. Tachibana A, Santos MR, Mahmoudi M, et al. Paracrine effects of the pluripotent stem cell-derived cardiac myocytes salvage the injured myocardium. Circ Res. 2017;121(6):e22-e36.
7. Gallet R, Dawkins J, Valle J, et al. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodeling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017;38(3):201-211.
8. Agarwal U, George A, Bhutani S, et al. Experimental, systems, and computational approaches to understanding the microRNA-mediated reparative potential of cardiac progenitor cell-derived exosomes from pediatric patients. Circ Res. 2017;120(4):701-712.
9. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015;117(1):52-64.
10. Oh JG, Watanabe S, Lee A, et al. miR-146a suppresses SUMO1 expression and induces cardiac dysfunction in maladaptive hypertrophy. Circ Res. 2018;123(6):673-685.
11. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014;124(5):2136-2146.
12. Halkein J, Tabruyn SP, Riecke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143-2154.
13. Loyer X, Zlatanova I, Devue C, et al. Intra-cardiac release of extracellular vesicles shapes inflammation following myocardial infarction. Circ Res. 2018;123(1):100-106.
14. Gouin K, Peck K, Antes T, et al. A comprehensive method for identification of suitable reference genes in extracellular vesicles. J Extrav Cell Vesicles. 2017;6(1):1347019.
15. Xiang M, Zeng Y, Yang R, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 2014;454(1):210-214.
16. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72(13):1443-1452.
17. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14(5):844-852.
18. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008;9:76.
19. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-1006.
20. Ishiguro K, Yan IK, Patel T. Isolation of tissue extracellular vesicles from the Liver. J Vis Exp. 2019.
21. Alexander M, Hu R, Runtsch MC, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;6:7321.
22. Castoldi M, Schmidt S, Benes V, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006;12(5):913-920.
23. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database–2009 update. Nucleic Acids Res. 2009;37(Database):D767-D772.
24. Jensen LJ, Kuhn M, Stark M, et al. STRING 8—a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database):D412-D416.
25. Buzas EI, Toth EA, Szabo-BW, Szabo-Taylor KE. Molecular interactions at the surface of extracellular vesicles. Semin Immunopathol. 2018;40(5):453-464.

26. Gidlof O, Evander M, Rezeli M, Marko-Varga G, Laurell T, Erlinge D. Proteomic profiling of extracellular vesicles reveals additional diagnostically important markers for myocardial infarction compared to plasma alone. Sci Rep. 2019;9(1):8991.

27. Yang VK, Loughran KA, Meola DM, et al. Circulating exosome microRNA associated with heart failure secondary to myocardial mitral valve disease in a naturally occurring canine model. J Extracell Vesicles. 2017;6(1):1350088.

28. Minghua W, Zhijian G, Chahua H, et al. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-24. Cell Death Dis. 2018;9(3):320.

29. Takawale A, Zhang P, Patel VB, Wang X, Oudit G, Kassiri Z. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-Integrin beta1 interaction. Hypertension. 2017;69(6):1092-1103.

30. Eassondh K, Deng S, Wang X, et al. Tsg101 positively regulates physiologic-like cardiac hypertrophy through FIP3-mediated endosomal recycling of IFG-1R. FASEB J. 2019;33(6):7451-7466.

31. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun. 2013;4:2980.

32. Ming S, Shui-Yun W, Wei Q, et al. miR-139-5p inhibits isoprostane-mediated cardiac hypertrophy by targeting c-Jun. Biosci Rep. 2018;38(2).

33. Hu ZQ, Luo JF, Yu XJ, et al. Targeting myocardocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice. Oncotarget. 2017;8(54):92079-92089.

34. Ganesan J, Ramanujam D, Sassi Y, et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013;127(21):2097-2106.

35. Yuan J, Liu H, Gao W, et al. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress. Theranostics. 2018;8(9):2565-2582.

36. Jiang C, Tong Z, Fang WL, et al. Microrna-139-5p inhibits epithelial-mesenchymal transition and fibrosis in post-menopausal women with interstitial cystitis by targeting LPAR4 via the PI3K/Akt signaling pathway. J Cell Biochem. 2018;119(8):6429-6441.

37. Chen W, Zhao W, Yang A, et al. Integrated analysis of microRNA and gene expression profiles reveals a functional regulatory module associated with liver fibrosis. Gene. 2017;636:87-95.

38. Zhao Y, Yan M, Chen C, et al. MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart. Oncotarget. 2018;9(18):14382-14396.

39. Bao Q, Chen L, Li J, et al. Role of microRNA-124 in cardiomyocyte hypertrophy induced by angiotensin II. Cell Mol Biol (Noisy-le-grand). 2017;63(4):23-27.

40. Cai K, Chen H, MiR-625-5p inhibits cardiac hypertrophy through targeting STAT3 and CaMKII. Hum Gene Ther Clin Dev. 2019.

41. Battle M, Castillo N, Alcarraz A, et al. Axil expression is increased in early stages of left ventricular remodeling in an animal model with pressure-overload. PLoS ONE. 2019;14(6):e0217926.

42. Sunamura S, Sato K, Kurosawa R, et al. Different roles of myocardial ROCK1 and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in mice. Proc Natl Acad Sci USA. 2018;115(30):E7129-E7138.

43. Derda AA, Woo CC, Wongsurawat T, et al. Gene expression profile analysis of aortic vascular smooth muscle cells reveals upregulation of cadherin genes in myocardial infarction patients. Physiol Genomics. 2018;50(8):648-657.

44. Rose BA, Yokota T, Chintalagattu V, et al. Cardiac myocyte p38alpha kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart. J Biol Chem. 2017;292(31):12787-12800.

45. Han Y, Wang Q, Fan X, et al. Epigallocatechin gallate attenuates overload-induced cardiac ECM remodeling via restoring T cell homeostasis. Mol Med Rep. 2017;16(3):3542-3550.

46. Li Q, Xie J, Wang B, et al. Overexpression of microRNA-99a attenuates cardiac hypertrophy. PLoS ONE. 2016;11(2):e0148480.

47. Jeong D, Lee MA, Li Y, et al. Matricellular protein CCN5 reverses established cardiac fibrosis. J Am Coll Cardiol. 2016;67(13):1556-1568.

48. Yu Z, Zhang H, Yu M, Ye Q. Analysis of gene expression during the development of congestive heart failure after myocardial infarction in rat models. Int Heart J. 2015;56(4):444-449.

49. Oka S, Zhai P, Yamamoto T, et al. Peroxisome proliferator activated receptor-alpha association with silent information regulator 1 suppresses cardiac fatty acid metabolism in the failing heart. Circ Heart Fail. 2015;8(6):1123-1132.

50. Rafiq K, Kolpakov MA, Seqqat R, et al. c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia. Circulation. 2014;129(20):2031-2043.

51. Perrino C, Naga Prasad SV, Schroder JN, Hata JA, Milano C, Rockman HA. Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. Circulation. 2005;111(20):2579-2587.

52. Nie X, Fan J, Li H, et al. miR-217 promotes cardiac hypertrophy and dysfunction by targeting PTEN. Mol Ther Nucleic Acids. 2018;12:254-266.

53. Lalem T, Zhang L, Scholz M, et al. Cyclin dependent kinase inhibitor 1C is a female-specific marker of left ventricular function after acute myocardial infarction. Int J Cardiol. 2018;274:319-325.

54. Cao Q, Zhang J, Gao L, Zhang Y, Dai M, Bao M. Dickkopf3 upregulation mediates the cardioprotective effects of curcumin on chronic heart failure. Mol Med Rep. 2018;17(5):7249-7257.

55. Tie Y, Zhai C, Zhang Y, et al. CCAAT/enhancer-binding protein beta overexpression alleviates myocardial remodelling by regulating angiotsin-converting enzyme-2 expression in diabetes. J Cell Mol Med. 2017;21(3):1457-1468.

56. Wu C, Dong S, Li Y. Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload. Int J Mol Med. 2015;35(4):893-900.

57. Thomas RL, Roberts DJ, Kubil DA, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27(12):1365-1377.

58. Awazawa M, Gabel P, TsaoSioodio E, et al. A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle. Nat Med. 2017;23(12):1466-1473.

59. Zhang WW, Bai F, Wang J, et al. Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotsin II AT1 receptor. Drug Des Devel Ther. 2017;11:3019-3033.

60. Khadekar A, Springer S, Wang W, et al. Notch-mediated epigenetic regulation of voltage-gated potassium currents. Circ Res. 2016;119(12):1324-1338.

61. Salvador AM, Nevers T, Velazquez F, et al. Intercellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure. J Am Heart Assoc. 2016;5(3):e003126.

62. Watanabe S, Horie T, Nago K, et al. Cardiac-specific inhibition of kinase activity in calcium/calmodulin-dependent protein kinase kinase-beta leads to accelerated left ventricular remodeling and...
heart failure after transverse aortic constriction in mice. PLoS ONE. 2014;9(9):e108201.

63. Deng KQ, Li J, She ZG, et al. Restoration of circulating MFGE8 (Milk Fat globule-EGF Factor 8) attenuates cardiac hypertrophy through inhibition of akt pathway. Hypertension. 2017;70(4):770-779.

64. Jebessa ZH, Shanmukha Kumar D, Dewenter M, et al. The lipid droplet-associated protein ABHD5 protects the heart through proteolysis of HDAC4. Nat Metab. 2019;1(11):1157-1167.

65. Bryant SM, Kong CHT, Watson JJ, et al. Caveolin 3-dependent loss of t-tubular ICa during hypertrophy and heart failure in mice. Exp Physiol. 2018;103(5):652-665.

66. Mohamed TMA, Ang YS, Radzinsky E, et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell. 2018;173(1):104-116.e12.

67. You XY, Huang JH, Liu B, Liu SJ, Zhong Y, Liu SM. HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochemistry (Mosc). 2014;79(6):538-544.

68. Du W, Liang H, Gao X, et al. MicroRNA-328, a potential anti-fibrotic target in cardiac interstitial fibrosis. Cell Physiol Biochem. 2018;39(3):827-836.

69. Li C, Li X, Gao X, et al. MicroRNA-328 as a regulator of cardiac hypertrophy. Int J Cardiol. 2014;173(2):268-276.

70. Ai P, Shen B, Pan H, Chen K, Zheng J, Liu F. MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1alpha. J Thromb Thrombolysis. 2018;45(2):264-273.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Oh JG, Lee P, Gordon RE, Sahoo S, Kho C, Jeong D. Analysis of extracellular vesicle miRNA profiles in heart failure. J Cell Mol Med. 2020;24:7214–7227. https://doi.org/10.1111/jcmm.15251